Ibalizumab

From Wikipedia, the free encyclopedia

 This article does not cite any references or sources. (July 2007)
Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed.


Ibalizumab?
Therapeutic monoclonal antibody
Source Human
Target CD4
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Ibalizumab (also known as TNX-355) is a monoclonal antibody which it is used as an immunosuppresive drug, and it is used in the treatment of HIV/AIDS.

Pills  This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)
"-lizu-" (immune system)
"-bazu-" (bacterial)
"-cizu-" (cardiovascular)
"-neuzu-" (nervous system)
"-toxazu-" (toxin as target)
"-vizu-" (viral infections)
v • d • e
Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04)
Monoclonal antibodies
TNF inhibitors (Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
-imus
-cept (Fusion protein)
Other
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Entry/fusion inhibitors
Enfuvirtide • Maraviroc • Vicriviroc† • PRO 140† • Ibalizumab†
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. §Development terminated.